[go: up one dir, main page]

Lee et al., 2011 - Google Patents

Assessment of heparin anticoagulation by Sonoclot Analyzer in arterial reconstruction surgery

Lee et al., 2011

Document ID
8415670726962615673
Author
Lee B
Al-Waili N
Butler G
Salom K
Publication year
Publication venue
Technology and Health Care

External Links

Snippet

Since heparin has been in use as an anticoagulant during vascular surgery and medical problems such as DVT or pulmonary embolism, there has been no consensus as to the best method of monitoring its effect on anticoagulation. In this study we used Sonoclot Analyzer to …
Continue reading at journals.sagepub.com (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G01N33/487—Physical analysis of biological material of liquid biological material
    • G01N33/49—Blood
    • G01N33/4905—Determining clotting time of blood
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/80—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood groups or blood types or red blood cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/22—Haematology
    • G01N2800/226—Thrombotic disorders, i.e. thrombo-embolism irrespective of location/organ involved, e.g. renal vein thrombosis, venous thrombosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans

Similar Documents

Publication Publication Date Title
JP7246559B2 (en) Detection and Classification of Anticoagulants Using Coagulation Analysis
Artang et al. Fully automated thromboelastograph TEG 6s to measure anticoagulant effects of direct oral anticoagulants in healthy male volunteers
Lindhoff-Last et al. Assays for measuring rivaroxaban: their suitability and limitations
Whiting et al. TEG and ROTEM: technology and clinical applications
Eikelboom et al. Monitoring unfractionated heparin with the aPTT: time for a fresh look
AU2001275249B2 (en) Method and apparatus for monitoring anti-platelet agents
Schöchl et al. Thromboelastometry (TEM®) findings in disseminated intravascular coagulation in a pig model of endotoxinemia
Byun et al. Establishing the heparin therapeutic range using aPTT and anti-Xa measurements for monitoring unfractionated heparin therapy
Kashuk et al. Noncitrated whole blood is optimal for evaluation of postinjury coagulopathy with point-of-care rapid thrombelastography
AU2001275249A1 (en) Method and apparatus for monitoring anti-platelet agents
Teruya et al. Monitoring bivalirudin therapy in children on extracorporeal circulatory support devices: Thromboelastometry versus routine coagulation testing
Taune et al. Whole blood coagulation assays ROTEM and T-TAS to monitor dabigatran treatment
Lee et al. Assessment of heparin anticoagulation by Sonoclot Analyzer in arterial reconstruction surgery
Yates et al. Can an anti-Xa assay for low-molecular-weight heparin be used to assess the presence of rivaroxaban?
Stone et al. Heparin rebound: An in-depth review
Petričević et al. Definition of acetylsalicylic acid resistance using whole blood impedance aggregometry in patients undergoing coronary artery surgery
Chiasakul et al. Laboratory monitoring of heparin anticoagulation in hemodialysis: Rationale and strategies
Yetman et al. Apixaban pharmacodynamic activity in umbilical cord, paediatric, and adult plasma
Narani Thrombelastography in the perioperative period
Reiss et al. Point‐of‐care versus laboratory monitoring of patients receiving different anticoagulant therapies
Akay et al. The Evaluation of Hydroxyethyl Starch (6% HES 130/0.4) Solution's Potential Preventive Effects on Coagulation Status in Women with Gynecologic Malignancies Using Rotation Thromboelastography/Jinekolojik Maligniteli Kadinlarda Hidroksietil Nisasta (% 6 HES 130/0.4) Solüsyonunun Potansiyel Koruyucu Etkilerinin Rotasyonel Trombelastografi Kullanilarak Degerlendirilmesi
Laffan et al. 18 Laboratory control of anticoagulant, thrombolytic, and antiplatelet therapy
Cuker et al. T2 magnetic resonance to monitor hemostasis
Zimmerman The role of point-of-care anticoagulation monitoring in arterial and venous thromboembolic disorders
Parker et al. Monitoring Unfractionated Heparin: A Review of Activated Partial Thromboplastin Time Versus Antifactor Xa